England’s National Health Service (NHS) says that it has saved £110 million (US $134 million) by implementing its policy to use the best-value adalimumab after the brand-name Humira lost European patent protection in October 2018.
England’s National Health Service (NHS) says that it has saved £110 million (US $134 million) by implementing its policy to use the best-value adalimumab after the brand-name Humira lost European patent protection in October 2018.
Prior to its loss of patent protection, AbbVie’s Humira was the single medicine on which NHS hospitals spent the most, at £400 million (US $487 million) each year. In preparation for biosimilar availability, the NHS used an approach in which it awarded lots of the adalimumab market to multiple adalimumab manufacturers, and the size of each lot was dependent upon the strength of the offers that drug makers made during the tendering process. The biosimilars now available under the NHS system are Amgen’s Amgevita, Samsung Bioepis’ Imraldi, Sandoz’s Hyrimoz, and Mylan’s Hulio.
The newly announced savings from biosimilar adalimumab come in addition to the £413 million (US $503 million) saved over the past 2 years through the NHS’ concerted efforts to use generics and biosimilars, and the NHS says that it will also “accelerate and widen the uptake of best value biologic medicines” in an effort to save another £400 million to £500 million (US $487 million to $609 million) per year by 2020-2021.
Among the other savings generated during 2018-2019 are £32 million (US $39 million) from biosimilar infliximab, £36 million (US $44 million) from biosimilar etanercept, £45 million (US $55 million) from biosimilar rituximab, and £24 million (US $29 million) from biosimilar trastuzumab.
These savings will be reinvested in new, innovative treatments, says the NHS, noting that “These benefits have only been possible by working closely with patients, clinical teams and NHS trusts.”
Simon Stevens, the NHS’ chief executive, said in a statement that “Use of the best value versions of expensive medicines is already delivering effective treatment for patients across the NHS, including those with cancer, offering the right care for patients while saving the tax payer hundreds of millions of pounds.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.